Kidney transplantation is the best treatment for end-stage renal disease patients. However, the relative shortage of organs for transplantation has led to ABO-incompatible kidney transplantation as an accepted method to expand the pool of kidney donors. Recent advances in immunosuppression and antibody removal methods have made ABO-incompatible kidney transplantation more feasible, and have increased the opportunities for patients to receive kidney transplantation, as well as for special patients with ABO-compatible donor. Indeed, the outcome of ABO-incompatible kidney transplantation has shown remarkable developments and is now comparable to that of ABO-compatible kidney transplantation during last decade. However, there are still some uncertain issues to be addressed in ABO-incompatible kidney transplantation. In this article, we reviewed the current status and protocol of ABO-incompatible kidney transplantation and listed the concerns to be addressed in near future.

Citations

Citations to this article as recorded by  

• Formulation of the Scope and Key Questions of the Guideline Recommendations for Immunosuppressive Treatment in Kidney Transplantation
  Seungyeon Huh, Nayoung Han, Minji Sohn, Junghwa Ryu, Jaeseok Yang, Jung Mi Oh
  Korean Journal of Clinical Pharmacy.2019; 29(1): 18.     CrossRef
• Comparative Analysis of Effectiveness and Safety between High and Low Dose Rituximab in ABO-Incompatible Kidney Transplant Recipients
  문정은, 김재송, 손은선, 김효진
  Journal of Korean Society of Health-System Pharmacists.2017; 34(2): 200.     CrossRef